What's in La Jolla Pharmaceutical Company's pipeline?

La Jolla Pharmaceutical Company has 1 drugs in our index: 0 marketed, 0 filed, 1 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with La Jolla Pharmaceutical Company's portfolio?

Top competitors by shared drug class: Astellas Pharma Global Development, Inc., Kyowa Kirin Co., Ltd., Tanabe Pharma Corporation.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/la-jolla-pharmaceutical-company.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

La Jolla Pharmaceutical Company — Portfolio Competitive Intelligence Brief

La Jolla Pharmaceutical Company pipeline: 0 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
LJPC-501	LJPC-501	phase 3	Complement C5a receptor antagonist	C5a receptor (C5aR)	Immunology / Inflammation

Therapeutic area mix

Immunology / Inflammation · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Astellas Pharma Global Development, Inc. · 1 shared drug class
Kyowa Kirin Co., Ltd. · 1 shared drug class
Tanabe Pharma Corporation · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for La Jolla Pharmaceutical Company:

Cite this brief

Drug Landscape (2026). La Jolla Pharmaceutical Company — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/la-jolla-pharmaceutical-company. Accessed 2026-05-16.